東莨菪鹼 API 市場：按形式、按純度、按生產規模、按地區 - 規模、份額、展望、機會分析，2022-2030 年

東莨菪鹼是一種從紫莖澤蘭植物中提取的生物鹼藥物，用於治療噁心和暈動病，並在眼科手術中用於散瞳。東莨菪鹼屬於一類稱為抗膽鹼能藥的藥物。東莨菪鹼是一種從茄科植物中分離出來的托烷生物鹼，與阿托品和天仙子胺一樣，在結構上模仿天然神經遞質乙□膽鹼。通過抑制神經遞質乙□膽鹼的活性，該藥物通過刺激大腦中引發噁心和嘔吐、肺部、胃腸道和泌尿道的不自主肌肉運動的部分發揮作用。東莨菪鹼在醫療環境中用作鎮靜劑和催眠劑，有時與嗎啡一起用於緩解疼痛。東莨菪鹼也被規定為抑鬱症、哮喘、戒菸輔助劑和與化療相關的噁心的“標籤外”治療。

市場動態

東莨菪鹼通過其緩解焦慮作用（抗焦慮作用）有效緩解抑鬱和焦慮症狀。因此，由於越來越多的人患有焦慮症，預計預測期內的市場增長。例如，根據美國焦慮和抑鬱協會的數據，焦慮症是美國最常見的精神疾病，每年影響大約 4000 萬 18 歲及以上的成年人（佔人口的 18.1%）。我在這裡。

此外，預計在預測期內，越來越多地採用透皮貼劑等給藥系統也有望推動市場增長。東莨菪鹼透皮貼劑用於預防與麻醉和手術恢復相關的暈動病、噁心和嘔吐。

這項研究的主要特點

• 本報告對全球東莨菪鹼 API 市場進行了深入分析，提供了以 2021 年為基準年的預測期（2022-2030 年）的市場規模和復合年增長率 (CAGR%)。.
• 解釋了不同細分市場的潛在創收機會，並描述了針對該市場的有吸引力的投資建議矩陣。
• 它還提供有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
• 根據以下參數介紹全球東莨菪鹼 API 市場的主要參與者 - 公司亮點、產品組合、主要亮點、財務業績和戰略。
• 本研究涵蓋的主要公司包括 Phytex Australia、Aspen Holdings、LGM Pharma、Midas Pharma GmbH、Transo-Pharm Handels-GmbH、Aktin Chemicals, Inc、Merck KgaA、Alchem International Pvt. Ltd.、 Tiefenbacher API+Ingredients GmbH & Co. KG、Spectrum Chemical、Vital Laboratories Pvt Ltd、Clearsynth、Prism Industries Ltd、Alkaloids Corporation. 和 Manus Aktteva Biopharma LLP
• 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。看來。
• 《全球東莨菪鹼 API 市場報告》面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者可以通過用於分析全球東莨菪鹼 API 市場的各種戰略矩陣來促進他們的決策。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫說明

第二章市場展望

• 報告內容
  • 市場定義和範圍
• 執行摘要
  • 市場概況：按形態分類
  • 市場概況：按純度分類
  • 市場概況：按生產規模
  • 市場概況：按地區
• 連貫機會圖 (COM)

第3章市場動態、規律及趨勢分析

• 市場動態
  • 司機
  • 約束因素
  • 市場機會
• 影響分析
• 害蟲分析
• 監管情景
• 流行病學
• 收購/合同方案
• 主要亮點/發展
• 東莨菪鹼 API 市場的問題

第 4 章東莨菪鹼 API 的全球市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 經濟影響
• COVID-19 的流行病學特徵
• 供需分析

第 5 章。全球東莨菪鹼 API 市場，按形式，2017-2030

• 粉末
• 液體

第 6 章東莨菪鹼 API 的全球市場：按純度分類，2017-2030

• 99% 或更多
• 98% 或更多

第 7 章 2017-2030 年按生產規模分列的東莨菪鹼原料藥全球市場

• 工業規模
• 中試規模
• 實驗室規模

第 8 章按地區分列的東莨菪鹼原料藥全球市場，2017-2030

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地區
• 歐洲
• 英國
• 德國
• 意大利
• 法國
• 西班牙
• 俄羅斯
• 其他歐洲地區
• 亞太地區
• 中國
• 印度
• 日本
• 東盟
• 澳大利亞
• 韓國
• 其他亞太地區
• 中東
• 海灣合作委員會
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中非
• 南非

第9章競爭格局

• Phytex Australia.
• Aspen Holdings
• LGM Pharma
• Midas Pharma GmbH
• Transo-Pharm Handels-GmbH
• Aktin Chemicals,Inc
• Merck KGaA
• Alchem International Pvt. Ltd.
• Tiefenbacher API+Ingredients GmbH & Co. KG
• Spectrum Chemical
• Vital Laboratories Pvt Ltd
• Clearsynth
• Prism Industries Ltd
• Alkaloids Corporation.
• Manus Aktteva Biopharma LLP

第 10 章

• 調查方法
• 關於出版商

Scopolamine is an alkaloid drug extracted from a plant called henbane to treat nausea and motion sickness and further to dilate the pupil in ophthalmic procedures. Scopolamine belongs to a class of drugs called anticholinergic. Scopolamine is a tropane alkaloid isolated from members of the Solanaceae family of plants, similar to atropine and hyoscyamine, all of which structurally mimic the natural neurotransmitter acetylcholine. It works by blocking the activity of the neurotransmitter acetylcholine, which stimulates the part of the brain that triggers nausea and vomiting, involuntary muscle movement in the lungs, and the gastrointestinal and urinary tracts. Scopolamine is also used in medicine as a sedative or hypnotic and sometimes with morphine to relieve pain. Scopolamine has also been prescribed 'off label' for depression, asthma, as a smoking-cessation remedy, and to relieve the nausea that accompanies chemotherapy

Market Dynamics

Scopolamine is effective in reducing depression and anxiety symptoms due to its anxiety-reducing (anxiolytic) effects. Thus the increasing number of people suffering from anxiety is expected to drive the market growth over the forecast period. For instance, according to the Anxiety and Depression Association of America, anxiety disorders are the most common mental illness in the U.S. affecting about 40 million adults aged 18 years and older, or 18.1% of the population every year in the U.S.

Moreover, increasing adoption of drug delivery systems such as transdermal patches is expected to drive the market growth over the forecast period. The scopolamine transdermal skin patch is used to prevent nausea and vomiting caused by motion sickness or recovery from anesthesia and surgery.

Key features of the study:

• This report provides in-depth analysis of the global scopolamine API market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global scopolamine API market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Phytex Australia., Aspen Holdings, LGM Pharma, Midas Pharma GmbH, Transo-Pharm Handels-GmbH, Aktin Chemicals,Inc, Merck KgaA, Alchem International Pvt. Ltd., Tiefenbacher API + Ingredients GmbH & Co. KG, Spectrum Chemical, Vital Laboratories Pvt Ltd, Clearsynth, Prism Industries Ltd, Alkaloids Corporation., and Manus Aktteva Biopharma LLP
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global scopolamine API market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global scopolamine API market

Detailed Segmentation:

• Global Scopolamine API Market, By Form:
  • Powder
  • Liquid
• Global Scopolamine API Market, By Purity:
  • ≥99%
  • ≥ 98%
• Global Scopolamine API Market, By Scale of Production:
  • Industrial scale
  • Pilot scale
  • Laboratory scale
• Global Scopolamine API Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Phytex Australia.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Aspen Holdings
  • LGM Pharma
  • Midas Pharma GmbH
  • Transo-Pharm Handels-GmbH
  • Aktin Chemicals,Inc
  • Merck KGaA
  • Alchem International Pvt. Ltd.
  • Tiefenbacher API + Ingredients GmbH & Co. KG
  • Spectrum Chemical
  • Vital Laboratories Pvt Ltd
  • Clearsynth
  • Prism Industries Ltd
  • Alkaloids Corporation.
  • Manus Aktteva Biopharma LLP

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Form
  • Market Snapshot, By Purity
  • Market Snapshot, By Scale of Production
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• PEST Analysis
• Regulatory Scenario
• Epidemiology
• Acquisition/Agreement Scenario
• Key Highlights/Developments
• Challenges in Scopolamine API Market

4. Global Scopolamine API Market- Impact of Coronavirus (Covid-19) Pandemic

• Economic Impact
• COVID-19 Epidemiology
• Demand and Supply Analysis

5. Global Scopolamine API Market, By Form, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Powder
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Liquid
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Scopolamine API Market, By Purity, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• ≥99%
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• ≥ 98%
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Scopolamine API Market, By Scale of Production, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Industrial scale
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Pilot scale
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Laboratory scale
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Scopolamine API Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Purity, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Scale of Production, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Purity, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Scale of Production, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Purity, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Scale of Production, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Purity, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Scale of Production, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Purity, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Scale of Production, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Form, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Purity, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Scale of Production, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Phytex Australia.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Aspen Holdings
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• LGM Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Midas Pharma GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Transo-Pharm Handels-GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Aktin Chemicals,Inc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck KGaA
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Alchem International Pvt. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Tiefenbacher API + Ingredients GmbH & Co. KG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Spectrum Chemical
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Vital Laboratories Pvt Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Clearsynth
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Prism Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Alkaloids Corporation.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Manus Aktteva Biopharma LLP
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us